Heidi Feik

enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.

Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands.

Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ.

BioMotiv LLC operates as a research institution in the field of therapeutics. It focuses in disease areas and classes of therapeutics such as small molecules, antibodies, proteins, and nucleotides. The company was founded on September 10, 2012 and is headquartered in Cleveland, OH.

ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm offers fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands.

Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.

STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany.

Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands.

Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert.

DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom.

Scioto Biosciences, Inc. operates as a preclinical stage company. It develops therapies to transform the delivery of microbiome therapeutics. The firm?s platform enhances probiotics that are used for diabetes, neurological disorders, gastrointestinal health and alternatives to in-feed antibiotics. The company was founded by Joseph P. Trebley, Jim Schulz, Goodman Steve, Lauren O. Bakaletz, Michael Bailey and Gail E. Besner in May 2017 and is headquartered in Indianapolis, IN.

T3 Pharmaceuticals AG provides medicines and treatment for cancer patient. The company was founded in May 2015 by Simon J. Ittig, Christoph A. Kasper, Marlise Amstutz and Helmut H. Kessmann and is headquartered in Basel, Switzerland.

Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom.

HatchBox Bioconsulting LLC provides life science advisory services.

GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy.

Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom.

Covicept Therapeutics, Inc. is a newly founded company based in California, USA. Covicept Therapeutics is focused on developing drugs to treat diseases caused by a variety of RNA viruses, including SARS-CoV-2. The American company is backed by $2.30 million in seed funding and operational support from leading European VC firm Forbion. Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection, and replication of SARS-CoV-2 and other RNA viruses. PSJ-539 has shown good tolerability and high potency with excellent and high biodistribution to tissues, including the lungs, in humans, allowing for relatively low daily doses. PSJ-539 also inhibits fibrosis, a property that may be valuable for patients infected with SARS-CoV-2, both short term and long-term. The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and antiviral medications. The company was founded by Sam Tsimikas, Philip Gordts, and Jeffrey Esko. Sam Tsimikas has been the CEO since incorporation.

VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge.

GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020.

BioNeex, Inc. is an American company located in Syracuse, NY, that operates as a drug development platform. It was founded by Smbat Rafayelyan and Tigran Rafayelyan. Smbat Rafayelyan has been the CEO since 2018. The company says this about itself: BioNeex is the first R&D open exchange platform in the biopharma industry, facilitating licensing and co-development partnerships for preclinical and clinical-stage drug candidates between biotech, biopharma companies and research institutions. Data posted on the drug candidate marketplace is listed by biotech, biopharma companies, and research institutions, enabling potential licensing and co-development partners as well as investors to contact them directly with one click.

Vantage Biosciences Ltd. develops drugs for diabetic eye disease. The British company was founded by Andre Badalyan, Katie Sunnucks, Graeme R. Martin, Alek Safarian.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.